Technical Analysis for CXRXD - Concordia International

Grade Last Price % Change Price Change
grade A 20.594 -1.98% -0.4168
CXRXD closed down 1.98 percent on Friday, October 5, 2018, on 14 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical CXRXD trend table...

Date Alert Name Type % Chg

Older signals for CXRXD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Chemistry Medicine Health RTT Cancer Pharmaceutical Laser Arthritis Cancer Treatments Epilepsy Malaria Urinary Tract Infections Irritable Bowel Syndrome Laser Medicine Light Therapy Lupus Photodynamic Therapy Adjunctive Therapy Cystitis Bacterial Infection Bladder Infections Generic Prescription Products Levothyroxine Partial Seizures Porfimer Sodium Therapy For Irritable Bowel Syndrome Treatment Of Certain Forms Of Cancer
Is CXRXD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 21.0108
52 Week Low 17.7126
Average Volume 2,870
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 19.5114
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0916
MACD Signal Line 0.0183
MACD Histogram 0.0733
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.5963
Resistance 3 (R3) 20.5965 20.5960 20.5959
Resistance 2 (R2) 20.5960 20.5954 20.5959 20.5957
Resistance 1 (R1) 20.5950 20.5951 20.5948 20.5948 20.5956
Pivot Point 20.5945 20.5945 20.5944 20.5944 20.5945
Support 1 (S1) 20.5935 20.5939 20.5933 20.5933 20.5924
Support 2 (S2) 20.5930 20.5936 20.5929 20.5923
Support 3 (S3) 20.5920 20.5930 20.5921
Support 4 (S4) 20.5918